Adamis Pharmaceuticals Corp (ADMP)

Add to Watchlists
Create an Alert
0.56 +0.01  +1.10% NASDAQ Oct 22, 13:31 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/08/2020 17:00 EDT Misc Adamis Pharmaceuticals Corp First Quarter Earnings Conference Call in 2020
11/08/2019 Earnings Adamis Pharmaceuticals Corp Third Quarter Earnings Results in 2019
08/08/2019 17:00 EDT Misc Adamis Pharmaceuticals Corp Second Quarter Earnings Conference Call in 2019
08/08/2019 Earnings Adamis Pharmaceuticals Corp Second Quarter Earnings in 2019 Release
07/24/2019 13:00 PDT Misc Adamis Pharmaceuticals Corp Annual General Meeting in 2018
05/09/2019 17:00 EDT Misc Adamis Pharmaceuticals Corp First Quarter Earnings Conference Call in 2019
05/09/2019 Earnings Adamis Pharmaceuticals Corp First Quarter Earnings in 2019 Release
03/15/2019 Misc Adamis Pharmaceuticals Corp Annual Report in 2018
11/09/2018 Earnings Adamis Pharmaceuticals Corp Third Quarter Earnings Results in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.adamispharmaceuticals.com
  • Investor Relations URL: http://ir.adamispharmaceuticals.com/phoenix.zhtml?c=99350&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Nov. 08, 2019
  • Last Earnings Release: Aug. 08, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15 mg products were approved for use in emergency treatment of acute allergic reactions, including anaphylaxis. It previously announced a distribution and commercialization agreement with Sandoz to market Symjepi in the US. The company is developing additional products, including a sublingual tadalafil product candidate for the treatment of erectile dysfunction, a naloxone injection product for the treatment of opioid overdose, and metered dose inhaler and dry powder inhaler product candidates.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.